Photo via Daily Mail

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist

Read the original at Daily Mail ↗
Cite

Hynds, J. (2026, October 22). World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist. Daily Mail. https://www.dailymail.com/news/article-16231693/cancer-vaccine-trial-australia-georgina-long.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

Dated from the outlet's own feed. Check the original for its byline.

Daily Mail · collected 2026-10-23 · by Joanna Hynds

Quick Summary

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment, potentially improving survival rates for melanoma patients and possibly extending to other cancers as well.
Written by AI on 2026-10-23, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

AI analysis

Story summary

Moderna and MSD developed intismeran, a personalized mRNA-based vaccine, which when combined with Keytruda (pembrolizumab) reduced the risk of melanoma recurrence or death by 42% in patients two years after surgery. The trial included over 1,100 participants with high-risk melanoma that had been surgically removed. Intismeran targets up to 34 tumor neoantigens specific to each patient's tumor, enhancing the immune system’s ability to fight cancer. Although results are promising and could mark a turning point in personalized cancer treatment, longer-term studies are needed to confirm long-term benefits and impact on overall survival rates. The vaccine is currently experimental and not available on healthcare systems like NHS yet. Similar approaches are being tested for other cancers including kidney, bladder, and lung cancer. The detailed findings were initially scheduled to be presented at the European Society of Medical Oncology Congress but were released ahead of time due to data leaks. Lead researcher Professor Georgina Long from Melanoma Institute Australia described the results as "phenomenal" and potentially transformational for cancer treatment. Independent experts also view the outcome positively, though they emphasize the need for extended follow-up studies to establish definitive benefits in patient longevity.

Written for “mRNA Cancer Vaccine Breakthrough For Melanoma” on 2026-11-21, grounded in this article and the 7 other(s) covering the same event.

How they differ

8 outlets covered “mRNA Cancer Vaccine Breakthrough For Melanoma”.

What each outlet says

One AI summary per outlet of its latest article on this story, written from that article alone and checked against it. Open the article for the outlet's own words.

Daily MailThis outlet23 Oct

Professor Georgina Long led a world-first cancer vaccine trial that significantly reduced the risk of melanoma recurrence or death by 42% compared to patients treated with only pembrolizumab (Keytruda). The study, involving 1,137 participants across 157 global sites, tested an individualised mRNA vaccine called intismeran, developed by Moderna and MSD. This breakthrough could revolutionize cancer treatment…

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist (this article)
The Independent22 Oct

ModernA’s mRNA cancer vaccine combined with Merck's immunotherapy reduced melanoma recurrence or death risk by 42%, according to a Phase 3 clinical trial involving over 1,100 patients. The study also showed a 38% reduction in the spread of cancer and revealed that 82.2% of patients receiving both treatments remained cancer-free after two years compared to 70% for those treated with Keytruda alone. ModernA plans to…

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% →
Toronto Star22 Oct

Moderna and Merck released results from a major study showing that an mRNA-based cancer vaccine called intismeran significantly reduces by 42% the risk of melanoma returning two years after surgery. The personalized vaccine, which targets unique gene mutations in each patient's tumor, was administered alongside standard post-surgery treatment to over 1,100 people with high-risk melanoma. At the end of the trial, 82%…

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning →
Time23 Oct

Moderna and Merck announced on October 22 that their customized cancer vaccine for late-stage melanoma reduces recurrence or death risk by 42% over two years compared to standard treatment. The study involved more than 1,130 patients who had tumors surgically removed and were then given either the intismeran vaccine (along with Keytruda) or a placebo plus Keytruda. Intismeran uses mRNA technology to help immune…

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% →
ABC News (AU)23 Oct

Researchers led by Australia have developed a world-first cancer vaccine that significantly reduces the risk of melanoma recurrence by 42 percent, according to phase 3 trial results. The study, set to be published in the New England Journal of Medicine, involved 1,137 patients and compared personalized mRNA-based vaccines combined with immunotherapy against immunotherapy alone. The treatment identifies unique…

Australia at the heart of 'transformational' cancer vaccine breakthrough →
BBC23 Oct

A new personalized cancer vaccine, when combined with an existing immunotherapy drug called Keytruda, has shown significant promise in reducing the recurrence and spread of melanoma by 42% and 38%, respectively, over two years. This trial involved more than 1,100 patients who had their tumors surgically removed. The vaccine, named Intismeran, uses mRNA technology similar to that used in some COVID vaccines, tailored…

First personalised cancer vaccine cuts risk of disease returning in major trial →
Show 2 more outlets
Evening Standard23 Oct

A large trial has shown that a personalized mRNA cancer vaccine for melanoma reduces the risk of recurrence or death by 42% when used with immunotherapy. The study involved over 1,100 high-risk melanoma patients who had surgery to remove their tumors. This vaccine works by targeting specific markers on each patient’s tumor and activating an immune response against these unique cancer mutations. The combination…

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% →
CBC23 Oct

Moderna and Merck released results from a major study showing their mRNA-based personalized cancer vaccine, intismeran, significantly reduces the risk of melanoma recurrence by 42% when used in conjunction with an existing treatment. The vaccine is tailored to each patient based on unique genetic mutations found in their tumor, leveraging mRNA technology similar to that used in COVID-19 vaccines. Dr. Hussein Tawbi…

A novel mRNA cancer vaccine helps cut the chances of melanoma tumor recurrence in major study →

Where they agree and split

Framing

How the first headlines put it

Stated as fact7
The headlines (7)

mRNA cancer vaccine slashes melanoma death or recurrence risk by 42% The Independent · stated as fact

A novel mRNA cancer vaccine helps reduce the chances of melanoma patients' tumors returning Toronto Star · stated as fact

A Personalized Cancer Vaccine Lowers Melanoma Recurrence by 42% Time · stated as fact

World-first cancer vaccine slashes death risk in stunning findings led by Aussie scientist Daily Mail · stated as fact

Australia at the heart of 'transformational' cancer vaccine breakthrough ABC News (Australia) · stated as fact

First personalised cancer vaccine cuts risk of disease returning in major trial BBC · stated as fact

World’s first mRNA cancer jab for melanoma cuts risk of death by 42% Evening Standard · stated as fact

The full story: what happened, how it changed, and all 8 articles →

Compared with similar articles

This article reads unscored and hedges 10% of its claims. Each row says how that neighbour differs.
The Independent
Hedges 0 of 16 claims Outlet record 59/100
TIME
Hedges 3 of 28 claims Outlet record 60/100
ABC News (AU)
Hedges 3 of 34 claims Outlet record 67/100
Evening Standard
Hedges 1 of 25 claims Outlet record 64/100
BBC News
Hedges 2 of 28 claims Outlet record 65/100
Toronto Star
Hedges 3 of 35 claims Outlet record 64/100
CBC News
Hedges 3 of 46 claims Outlet record 72/100

Story

mRNA Cancer Vaccine Breakthrough For Melanoma
Health · 8 article(s) covering the same event. Compare every outlet's account →
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
10
sentences that state something as happening or true
Uncertain
10%
1 of 10 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
69/100
Daily Mail's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
8
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-10-23 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

Daily Mail · 12223 article(s) · 25 correction(s) detected
Running correction rate · 25 correction(s)

Who wrote this

Joanna Hynds
65 article(s) here · 1 carrying a prediction
'I've been watching it for years, and Mr Albanese will shake hands poorly.
Khawaja admitted he was unsure what the fallout from the revelations could mean for his friendship with Cummins Khawaja has since cancelled several media appearances although he denied withdrawing from his book tour 'Sometimes I'm very specific on things, and sometimes I'm a bit vague on things, and I do it on purpose because I'm trying to tell a story.'
William, 17, went missing on October 6 after walking to another part of the campsite near Stoney Creek Road and T2 Track in the afternoon. He was found alive by a police helicopter on Thursday morning after an extensive search across rugged bushland near Walhalla East, about 180km east of Melbourne. In his first interview since being found, he revealed he survived on a family-sized packet of crisps, carefully rationing them over the first two days while waiting to be rescued.
William, whose last name has not been released, was on his first ever camping trip with a friend at Walhalla East in eastern Victoria on Friday afternoon when he walked to another part of the site near Stoney Creek Road and T2 Track but failed to return. The 17-year-old, who has level two autism requiring 'substantial' support, was wearing only a pair of shorts and work boots at the time.
William, whose last name has not been released, was staying at Walhalla East in eastern Victoria on Friday afternoon when he walked to another part of the site near Stoney Creek Road and T2 Track but failed to return.
ASIC alleges that between November 2020 and May 31, 2025, about 42,000 CommBiz customers were overcharged about $8.5 million in fees.
'Having a sexual interest in children can feel lonely and you may feel society doesn't understand your situation.'
Davide Tamburella was dismissed from La Costa Restaurant and Bar in Fortitude Valley on May 20.
The death was not being treated as suspicious and a report would be prepared for the coroner.
Dozens of David Jones stores across Australia are set to be closed, including five locations in Westfield shopping centres, as the retailer reviews its national footprint.
Also by Joanna Hynds
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 65 articles by Joanna Hynds →

Topics

Keytruda Melanoma Institute Australia Sydney intismeran the University of Sydney

Subjects

Georgina Long PERSON · 2× Melanoma Institute Australia ORG · 2× Australian NORP · 1× Long PERSON · 1× MSD ORG · 1× Moderna ORG · 1× NSW GPE · 1× Sydney GPE · 1× Westmead Hospital ORG · 1× the University of Sydney ORG · 1×

Narrative

Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning.
framing: assertive · carried by 1 article(s) · first seen 2026-10-23
The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers.

Claims (10 extracted, 1 hedged)

A Sydney scientist is leading a world-first cancer vaccine trial that has dramatically reduced the risk of melanoma returning or patients dying from the disease. asserted
melanoma → lead → disease
The study found the vaccine cut the risk of cancer recurrence or death by 42 per cent compared with patients who received only an immunotherapy drug, pembrolizumab, which is sold under the brand name Keytruda. asserted
which → find → name
The landmark findings could pave the way for personalised cancer vaccines to improve survival rates for patients with melanoma and potentially other cancers. uncertain
vaccines → pave → melanoma
'These results show that patients with earlier-stage melanoma can be treated after surgery in a fundamentally new way,' Professor Long said. ' asserted
Long → show → way
Just as email transformed how we communicate, individualised neoantigen therapy has the potential to transform how we treat cancer. asserted
we → transform → cancer
The vaccine, known as intismeran, is being jointly developed by pharmaceutical companies Moderna and MSD. asserted
vaccine → know → companies
Intismeran is an individualised messenger RNA (mRNA) cancer vaccine designed specifically for each patient, based on the unique genetic characteristics of their tumour. asserted
Intismeran → design → tumour
Professor Georgina Long (pictured) led the clinical trial of a world-first cancer vaccine that dramatically reduced the risk of melanoma recurrence or death The trial was conducted across 157 sites worldwide and involved 1,137 patients whose melanoma had been surgically removed but who remained at high risk of the cancer returning. asserted
cancer → picture → risk
None of the participants had previously received drug treatment for their cancer. asserted
None → receive → cancer
The trial ran across a host of Australian sites, including Melanoma Institute Australia, Westmead Hospital in NSW, Princess Alexandra Hospital in Queensland, and the Paula Fox Melanoma and Cancer Centre and Peter MacCallum Cancer Centre in Victoria. asserted
trial → run → Victoria
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support